鼻咽癌
细胞毒性T细胞
肿瘤浸润淋巴细胞
免疫检查点
免疫组织化学
免疫疗法
癌症研究
医学
抗原
淋巴细胞
免疫系统
免疫学
生物
内科学
放射治疗
体外
生物化学
作者
Mohammed Ahmed,Manar G Gebriel,Emad A Morad,Ibrahim Saber,Amira Elwan,Mona Salah,Ahmed Elsadek Fakhr,Abdalla Shalaby,Mohamed Ali Alabiad
出处
期刊:Applied Immunohistochemistry & Molecular Morphology
日期:2021-01-15
卷期号:29 (6): 401-408
被引量:10
标识
DOI:10.1097/pai.0000000000000903
摘要
Nasopharyngeal carcinoma (NPC) is the most common cancer arising from the nasopharynx with a poor prognosis. Targeting immune checkpoint is one of the new promising lines in cancer treatment. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-ligand 1 (PD-L1) are immune checkpoints that regulate T-cell immune function.This work aimed to assess the immunohistochemical expression of PD-L1 and CTLA-4 in NPC and their ability to predict survival and response therapy and to check their validity as immunotherapy targets. Twenty-six cases of NPC were studied by immunohistochemistry for PD-L1 and CTLA-4 and by nested polymerase chain reaction followed by DNA sequencing for the presence of EBNA-1 gene of Epstein-Barr virus (EBV). All investigated cases were diagnosed and treated in the Zagazig University Hospital in the period from August 2015 to July 2018. EBNA-1 gene was identified in 84.6% of the cases. Whereas the expression of PD-L1 was noted in 46.2% of all cases studied, 54.6% of EBV-associated NPCs were found to express PD-L1. There was a significant association between PD-L1 expression and the advanced stage of the tumor (P<0.001). CTLA-4 expression was observed in 88.4% of all NPC cases as cytoplasmic staining in both tumor cells and tumor-infiltrating lymphocytes. CTLA-4 expression in lymphocytes was associated with the presence of EBV. A significant association was detected between CTLA-4 and tumor-infiltrating lymphocyte expression on one side and the stage of the tumor on the other. High expression of CTLA-4 was significantly associated with disease progression and worse overall survival.PD-L1 and CTLA-4 are adverse prognostic markers in NPC. The authors propose that targeted therapy against PD-L1 and CTLA-4 will be a hopeful therapy for cases of NPC with resistance to concurrent chemoradiation treatment in Egypt, especially EBV-associated cases.
科研通智能强力驱动
Strongly Powered by AbleSci AI